ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Boehringer Ingelheim licenses bacteriophage-derived lysin therapies from Bioharmony

by Ryan Cross
January 18, 2019 | APPEARED IN VOLUME 97, ISSUE 3

 

Boehringer Ingelheim is taking a new approach to fighting antibiotic-resistant bacteria. The German drug giant has struck a licensing and research agreement with the New York City–based start-up Bioharmony Therapeutics to develop therapies out of lysins, enzymes made by the bacteria-killing viruses called bacteriophages. Bioharmony hopes its lysins, based on work by microbiologist Vincent A. Fischetti at Rockefeller University, can tackle multidrug-resistant Gram-negative bacteria, which are considered some of the toughest to kill.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment